Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Operating Leases: 2020-2024

Historic Operating Leases for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $4.7 million.

  • BridgeBio Pharma's Operating Leases rose 49.51% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 49.51%. This contributed to the annual value of $4.7 million for FY2024, which is 47.71% down from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Operating Leases is $4.7 million, which was down 47.71% from $9.0 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Operating Leases peaked at $17.4 million during FY2021, and registered a low of $4.7 million during FY2024.
  • Its 3-year average for Operating Leases is $8.7 million, with a median of $9.0 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first grew by 18.74% in 2021, then plummeted by 47.71% in 2024.
  • BridgeBio Pharma's Operating Leases (Yearly) stood at $14.7 million in 2020, then climbed by 18.74% to $17.4 million in 2021, then declined by 29.57% to $12.3 million in 2022, then decreased by 26.83% to $9.0 million in 2023, then slumped by 47.71% to $4.7 million in 2024.